10-Q: Syra Health Narrows Loss, Shifts Revenue Focus

Syra Health Corp. reported a significant reduction in net loss for Q2 2025, driven by improved gross margins and cost reductions, despite a shift in revenue mix from healthcare workforce to population health services.

Summary

• Net loss for the three months ended June 30, 2025, was $(63,596), a significant decrease from $(1,390,256) for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $(535,861), a substantial improvement from $(2,837,306) for the same period in 2024.
• Gross profit margin increased to approximately 39% for the three months ended June 30, 2025, compared to 18% in the prior year period.
• Gross profit margin increased to approximately 35% for the six months ended June 30, 2025, compared to 14% in the prior year period.
• Total net revenues for the three months ended June 30, 2025, were $1,946,199, a 1% decrease from $1,969,681 in the prior year period.
• Total net revenues for the six months ended June 30, 2025, were $3,803,973, a 2% increase from $3,722,021 in the prior year period.
• Healthcare workforce revenue decreased by $1,053,787 (74%) for Q2 2025 and $1,816,231 (64%) for H1 2025.
• Population health revenue increased by $1,050,727 (197%) for Q2 2025 and $1,920,278 (222%) for H1 2025.
• Operating expenses decreased by $924,307 (53%) for Q2 2025 and $1,485,058 (44%) for H1 2025.
• Cash and cash equivalents as of June 30, 2025, were $2,305,924, down from $2,395,405 as of December 31, 2024.
• Working capital as of June 30, 2025, was $2,377,430, compared to $2,739,246 as of December 31, 2024.
• The accumulated deficit increased to $(9,360,054) as of June 30, 2025, from $(8,824,193) as of December 31, 2024.
• Net cash provided by operating activities for the six months ended June 30, 2025, was $85,754, a significant improvement from cash used of $2,304,012 in the prior year period.

Sentiment

Score: 6

Explanation: While the company shows significant improvements in profitability and operational efficiency, and a positive shift in revenue mix, the "going concern" warning and reliance on future capital raises, coupled with government spending uncertainties, temper the overall positive sentiment. The delisting from Nasdaq is also a negative factor.

Positives

• Net loss significantly decreased by $1,326,660 for the three months ended June 30, 2025, and by $2,301,445 for the six months ended June 30, 2025, compared to the prior year periods.
• Gross profit margin increased substantially to 39% for Q2 2025 (from 18% in Q2 2024) and 35% for H1 2025 (from 14% in H1 2024), driven by decreased labor and consulting costs and a favorable service mix shift.
• Operating expenses decreased by 53% for Q2 2025 and 44% for H1 2025, primarily due to reductions in salaries and benefits, research and development, and selling, general, and administrative expenses.
• Population Health revenue increased significantly by $1,050,727 (197%) for Q2 2025 and $1,920,278 (222%) for H1 2025, indicating successful diversification and growth in this segment.
• Achieved positive cash flow from operating activities of $85,754 for the six months ended June 30, 2025, a substantial improvement from cash used of $2,304,012 in the prior year period.

Negatives

• Overall net revenue slightly decreased by 1% for the three months ended June 30, 2025, compared to the same period in 2024.
• Healthcare workforce revenue significantly decreased by $1,053,787 (74%) for Q2 2025 and $1,816,231 (64%) for H1 2025, due to fewer new customer acquisitions and lower renewal value on a key FSSA contract.
• Delisted Class A common stock from the Nasdaq Capital Market on April 11, 2025, due to non-compliance with the minimum $1.00 bid price requirement.
• The company's ability to continue as a going concern is in substantial doubt, as existing liquidity and expected cash from sales may not be sufficient for the next twelve months.
• Heavy dependence on state, local, and county government budgets for revenue, with potential negative impacts from federal spending program pauses or terminations, leading to delays or cancellations of contracts.
• Cash and cash equivalents decreased by $89,481 for the six months ended June 30, 2025.
• Accumulated deficit increased to $(9,360,054) as of June 30, 2025.

Risks

• Projected financial position and estimated cash burn rate.
• Estimates regarding expenses, future revenues, and capital requirements.
• Ability to continue as a going concern.
• Need to raise substantial additional capital to fund operations.
• Ability to compete in the healthcare industry.
• Timing, cost, and success or failure of new product and service introductions, development, and product upgrade releases.
• Competitive pressures including offerings and pricing.
• Ability to establish and maintain strategic relationships.
• Undetected errors or similar problems in software products.
• Compliance with existing laws, regulations, and industry initiatives and future changes in laws or regulations in the healthcare industry.
• Possibility of services-related liabilities.
• Ability to obtain, maintain, and protect intellectual property rights and potential for substantial costs from lawsuits to enforce or protect intellectual property rights.
• Reliance on third-party content providers.
• Success of competing products or services that are or become available.
• Ability to expand organization to accommodate potential growth and ability to retain and attract key personnel.
• Successful development of sales and marketing capabilities.
• Dependence on state, local, and county government budgets for revenue, with potential for delays in new contract awards or cancellations due to federal spending program changes.

Future Outlook

The company expects potential negative effects on revenue, results of operations, and cash flows in the near term due to delays in new contract awards or cancellations of previous requests for proposals, stemming from the United States federal government pausing or terminating numerous spending programs that fund their customers. The company believes existing liquidity and expected cash from sales will not be sufficient to fund operations for the next twelve months and will require additional equity and/or debt financing.

Management Comments

• "We depend heavily on state, local and county government budgets for our revenue."
• "In 2025, the United States federal government began pausing or terminating numerous spending programs that potentially fund those programs and institutions that are our customers. As such, we have begun to see delays in new contract awards, or cancellations of previous requests for proposals."
• "These factors, and the possibility of further spending reviews and cancellations are expected to negatively affect the quantity and time of our revenue, results of operations and cash flows in the near term."
• "Our gross profit was approximately 39% for the three months ended June 30, 2025, compared to approximately 18% for the three months ended June 30, 2024, an increase of approximately 21%. Our cost of services decreased primarily due to a decrease in labor costs, and decreased consulting costs associated with a slight change in service mix from healthcare workforce services to project-based population health and digital health services that carry better margins."
• "Salaries and benefits decreased as our headcount decreased in 2025, and due to a strategic focus on streamlining our operations by reducing redundancies and optimizing our workforce."
• "The improvement in operating cash activities is a result of our efforts to reduce expenses and better working capital management."
• "We believe that our existing sources of liquidity, along with cash expected to be generated from sales and services, will not be sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements for at least the next twelve months from the issuance of the financial statements included elsewhere in this annual report."

Industry Context

The company operates in the healthcare services industry, focusing on preventative health, holistic wellness, health education, and equitable healthcare. The reclassification of digital health and health education revenues into the population health division indicates a strategic alignment with broader trends towards integrated population health management and digital solutions. The heavy reliance on government contracts exposes the company to shifts in public spending, a common challenge for government contractors in the healthcare sector. The decline in healthcare workforce revenue and growth in population health suggests a pivot towards higher-margin, project-based services, which aligns with industry trends emphasizing value-based care and data-driven health outcomes.

Management Changes

Corporate Governance

Legal Proceedings

• In January 2024, a former employee filed a wrongful termination lawsuit against the company in the U.S. District Court, Southern District of Indiana.
• In January 2025, the company entered into a settlement agreement with the former employee for an immaterial amount, and the case was dismissed.

Related Party Transactions

• Office Lease: The company leases its corporate headquarters from STVentures, LLC, an entity beneficially owned by the principal owners and management team of Syra and their affiliates. Rent expense was $67,253 for H1 2025 and $64,263 for H1 2024. The lease was amended in July 2025 to extend through June 30, 2027.
• Information Technology (IT) Services: Incurred $251,340 from RAD CUBE LLC (beneficially owned by principal owners/management) for outsourced IT services during H1 2025. No services were incurred in H1 2024.
• Recruitment and Human Resource Services: Paid $129,929 to NLogix IT Services Private Limited and $82,423 to SKL Demand Private Limited (both beneficially owned by principal owners/management) for services during H1 2025. Paid $297,313 to NLogix IT Services Private Limited during H1 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; uncertainty regarding going concern status; delisting from Nasdaq impacts liquidity and visibility; significant reduction in net loss and improved margins could be positive long-term.
• Employees: Headcount reduction in 2025 due to streamlining operations; changes in executive leadership (CEO termination and interim appointment) may create uncertainty.
• Customers: Shift in revenue mix from healthcare workforce to population health services; delays in new contract awards and potential cancellations from government agencies due to federal spending changes.
• Creditors: Notes payable repayments are ongoing; going concern uncertainty could impact future credit terms.
• Suppliers: Related party transactions for IT and HR services continue.

Next Steps

• Identify and hire a new permanent CEO.
• Develop a new strategic plan for the company.
• Retain key staff.
• Stabilize client relationships.
• Seek additional financing through debt and equity to fund operations.
• Monitor expenditures and cash flow position.

Key Dates

Recommendation

While the company demonstrated significant improvements in profitability, gross margins, and operating cash flow, driven by cost reductions and a strategic shift towards higher-margin population health services, substantial risks remain. The "going concern" warning, the delisting from Nasdaq, and the heavy reliance on government contracts subject to federal spending cuts introduce considerable uncertainty. The positive operational trends are encouraging, but the fundamental financial stability and capital needs warrant a cautious approach. An investor should hold to observe if the company successfully raises additional capital, stabilizes its government contract pipeline, and appoints a permanent CEO to execute a clear strategic plan.

Keywords

Healthcare services, Population health, Behavioral health, Mental health, Workforce staffing, SEC filing, 10-Q, Financial results, Quarterly report, Syra Health, SYRA, Corporate governance, Risk management, Nasdaq delisting, Going concern